Salvatore M. Aspromonte

MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation

S. Rabkin, H. Kaufman, P. Bommareddy, 2018, Science Translational Medicine.

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

S. Libutti, Evita T. Sadimin, W. El-Deiry, 2019, Journal of Immunotherapy for Cancer.